Alaunos Therapeutics Inc

Alaunos Therapeutics, Inc. is a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. Its approach is non-hormonal and non-incretin, unlike hormone-based treatments such as GLP-1 drugs. The company also develops the hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.